-+ 0.00%
-+ 0.00%
-+ 0.00%

The Safety Monitoring Committee Recommended Dose Escalation In Phio Pharmaceuticals' Phase 1b Trial For The Company's Lead Product Candidate, PH-762

Benzinga·04/09/2025 11:48:01
Listen to the news

Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. For these patients, injections were well tolerated with no serious adverse events and there were no dose-limiting toxicities. Pathology results related to efficacy of PH-762 in the third cohort are forthcoming.